The cohort was immunosuppressed at ART initiation, with a median CD4 count of 82 cells/mL (IQR 30–151), 45.7% with WHO stage III/IV, and 19.9% with a tuberculosis diagnosis. The gene discussed is CD4; the disease is tuberculosis.